Protagonist Therapeutics Inc. (PTGX) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Protagonist Therapeutics ... (PTGX)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

36.62

-0.52 (-1.40%)

At close: Jan 14, 2025, 3:59 PM

34.85

-4.84%

After-hours Jan 14, 2025, 05:31 PM EST

undefined% (undefined)

Bid	32.7
Market Cap	2.18B
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	2.74
PE Ratio (ttm)	13.36
Forward PE	n/a
Analyst	Buy

Ask	38.3
Volume	330,625
Avg. Volume (20D)	671,786
Open	37.29
Previous Close	37.14
Day's Range	36.45 - 37.32
52-Week Range	23.17 - 48.89
Beta	undefined

About PTGX

Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with polycythemia vera and hereditary hemochromatosis, as well as for the treatment of other blood disorder...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Aug 11, 2016

Employees 126

Stock Exchange NASDAQ

Ticker Symbol PTGX

Website https://www.protagonist-inc.com

Analyst Forecast

According to 8 analyst ratings, the average rating for PTGX stock is "Buy." The 12-month stock price forecast is $54.5, which is an increase of 48.83% from the latest price.

Buy 100.00%

Hold 0.00%

Sell 0.00%

Stock Forecasts

Next Earnings Release

Protagonist Therapeutics Inc. is scheduled to release its earnings on Feb 25, 2025, during market hours.
Analysts project revenue of $53.52M, reflecting a -10.8% YoY shrinking and earnings per share of 1.03, making a 134.09% increase YoY.

Why Price Moved

1 month ago · Source

+11.55%

Protagonist Therapeutics shares are trading higher... Unlock content with Pro Subscription

4 months ago · Source

+7.45%

Protagonist Therapeutics shares are trading higher after Truist Securities initiated coverage on the stock with a Buy rating and announced a price target of $60.

News

1 day ago · seekingalpha.com

Protagonist: Rusfertide PV Data Q1 2025 Isn't The Only 2025 Catalyst On Deck

Positive results achieved from both ICONIC studies using JNJ-2113 for the treatment of patients with moderate-to-severe plaque psoriasis; Superiority study is data expected in Q2 of 2025. Topline resu...

2 months ago · zacks.com

Protagonist Therapeutics (PTGX) Upgraded to Buy: Here's What You Should Know

Protagonist Therapeutics (PTGX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

2 months ago · zacks.com

Protagonist Therapeutics (PTGX) Reports Q3 Loss, Tops Revenue Estimates

Protagonist Therapeutics (PTGX) came out with a quarterly loss of $0.54 per share versus the Zacks Consensus Estimate of a loss of $0.59. This compares to loss of $0.58 per share a year ago.

3 months ago · zacks.com

Protagonist Therapeutics (PTGX) is on the Move, Here's Why the Trend Could be Sustainable

If you are looking for stocks that are well positioned to maintain their recent uptrend, Protagonist Therapeutics (PTGX) could be a great choice. It is one of the several stocks that passed through ou...